- Home
- MBC vs MNKD Comparison
MBC vs MNKD Comparison
Compare MBC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | MNKD |
|---|---|---|
| Founded | 1954 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | MBC | MNKD |
|---|---|---|
| Price | $11.54 | $5.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $15.00 | $10.08 |
| AVG Volume (30 Days) | 1.9M | ★ 2.8M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.63 | 0.10 |
| Revenue | ★ $2,757,800,000.00 | $313,787,000.00 |
| Revenue This Year | $0.91 | $21.54 |
| Revenue Next Year | N/A | $22.21 |
| P/E Ratio | ★ $18.50 | $60.68 |
| Revenue Growth | 1.77 | ★ 17.43 |
| 52 Week Low | $9.33 | $3.38 |
| 52 Week High | $18.15 | $7.07 |
Technical Indicators
Market Signals| Indicator | MBC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 62.87 |
| Support Level | $10.88 | $5.59 |
| Resistance Level | $12.02 | $6.01 |
| Average True Range (ATR) | 0.41 | 0.19 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 72.21 | 87.50 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.